News

A biologics license application (BLA) was submitted to the US Food and Drug Administration (FDA), while a Grouped Type II variation/extension application was filed with the European Medicines

CGS-200 is a novel high-strength topical formulation of the TRPV1 channel agonist trans-capsaicin combined with hyaluronic acid. It has been designed to deliver long-term desensitization of nerve fibers

The approval, which authorizes the sale of the product in all 28 member states of the European Union, follows the positive opinion from the European Medicines Agency’s Committee

Under the collaboration, the companies will research and develop potential new medicines directed at about 10 GPCR targets. Heptares will apply its GPCR structure-guided platform to help offer

Anamorelin HCI is a novel, orally active selective ghrelin receptor agonist being developed to treat anorexia, cachexia, or unintended weight loss in NSCLC patients. Helsinn said ghrelin is

KU is the US specialty generic pharmaceuticals subsidiary of biopharmaceuticals firm UCB. The acquisition creates a key player in drug industry. The combined company generated pro-forma revenues of

Bristol-Myers Squibb planned to use the drug a single agent to treat previously untreated patients, specifically those with BRAF V600 mutation positive unresectable or metastatic melanoma. The company

The facility, which will be built next to the company’s two existing plants, will have 180,000 liters of capacity. The company said in a filing that it expects

biOasis’ Transcend Platform was originally based on the protein known as melanotransferrin (MTf or p97). Researchers at biOasis hypothesized that smaller sequences within the 80 kDa protein would